1. Torre Lindsey, A, Trabert, Britton, DeSantis Carol, E, et al. Ovarian cancer statistics. CA Cancer J Clin 2018; 68: 284–296.
Google Scholar | Medline2. Chen, W, Zheng, R, Baade, PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–132.
Google Scholar | Crossref | Medline | ISI3. Ozols, RF, Bundy, BN, Greer, BE, et al. Gynecologic Oncology Group, phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–3200.
Google Scholar | Crossref | Medline | ISI4. Gupta, D, Lis, CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiologi- cal literature. Nutr J 2010; 9: 69.
Google Scholar | Crossref | Medline5. Jacobs, I, Oram, D, Fairbanks, J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97: 922–929.
Google Scholar | Crossref | Medline6. Soletormos, G, Duffy, MJ, Othman, Abu, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumour Markers. Int J Gynecol Cancer 2016; 26: 43–51.
Google Scholar | Crossref | Medline | ISI7. Moss, E, Hollingworth, J, Reynolds, T. The role of CA125 in clinical practice. J Clin Pathol 2005; 58: 308–312.
Google Scholar | Crossref | Medline | ISI8. Sjövall, K, Nilsson, B, Einhorn, N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 2002; 85: 175–178.
Google Scholar | Crossref | Medline9. Rosen, DG, Wang, L, Atkinson, JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267–277.
Google Scholar | Crossref | Medline | ISI10. Nossov, V, Amneus, M, Su, F, et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008; 199: 215–223.
Google Scholar | Crossref | Medline | ISI11. Schummer, M, Ng, WV, Bumgarner, RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999; 238: 375–385.
Google Scholar | Crossref | Medline12. Moore, RG, Brown, AK, Miller, MC, et al. The use of multiple novel tumour biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108: 402–408.
Google Scholar | Crossref | Medline | ISI13. Speeckaert, MM, Speeckaert, R, Delanghe, JR. Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumour marker. Adv Clin Chem 2013; 59: 1–21.
Google Scholar | Crossref | Medline14. Crowley, E, Di Nicolantonio, F, Loupakis, F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013; 10: 472.
Google Scholar | Crossref | Medline | ISI15. Giannopoulou, L, Kasimir-Bauer, S, Lianidou, ES. Liquid biopsy in ovarian cancer: recent advances on circulating tumour cells and circulating tumour DNA. Clin Chem Lab Med 2018; 56: 186–197.
Google Scholar | Crossref | Medline16. Marzese, DM, Hirose, H, Hoon, DS. Diagnostic and prognostic value of circulating tumour-related DNA in cancer patients. Expert Rev Mol Diagn 2013; 13: 827–844.
Google Scholar | Crossref | Medline17. Kuhlmann, JD, Schwarzenbach, H, Wimberger, P, et al. LOH at 6q and 10q in fraction- ated circulating DNA of ovarian cancer patients is predictive for tumour cell spread and overall survival. BMC Cancer 2012; 12: 325.
Google Scholar | Crossref | Medline18. Dawson, SJ, Tsui, DW, Murtaza, M, et al. Analysis of circulating tumour DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368: 1199–1209.
Google Scholar | Crossref | Medline | ISI19. Murtaza, M, Dawson, SJ, Tsui, DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108.
Google Scholar | Crossref | Medline | ISI20. Ni, X, Zhuo, M, Su, Z, et al. Reproducible copy number variation patterns among single circulating tumour cells of lung cancer patients. Proc Natl Acad Sci U S A 2013; 110: 21083–21088.
Google Scholar | Crossref | Medline21. Shaw, JA, Page, K, Blighe, K, et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 2012; 22: 220–231.
Google Scholar | Crossref | Medline22. Xia, S, Huang, CC, Le, M, et al. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. Lung Cancer 2015; 90: 78–84.
Google Scholar | Crossref | Medline23. Heitzer, E, Ulz, P, Belic, J, et al.Tumour-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 2013; 5: 30.
Google Scholar | Crossref | Medline24. Cohen, PA, Flowers, N, Tong, S, et al. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening. BMC Med 2016; 14: 126.
Google Scholar | Crossref | Medline25. Vanderstichele, A, Busschaert, P, Smeets, D, et al. Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses. Clin Cancer Res 2017; 23: 2223–2231.
Google Scholar | Crossref | Medline26. Wang, Y, Li, L, Douville, C, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med 2018; 10: eaap8793.
Google Scholar | Crossref | Medline27. Amant, F, Verheecke, M, Wlodarska, I, et al. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol 2015; 1: 814–819.
Google Scholar | Crossref | Medline28. Taylor, AM, Shih, J, Ha, G, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 2018;33:676 – 689.
Google Scholar | Crossref | Medline29. Hoadley, KA, Yau, C, Wolf, DM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158: 929–944.
Google Scholar | Crossref | Medline | ISI30. Liu, Y, Chen, C, Xu, Z, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature 2016; 53: 1471–475.
Google Scholar31. Sheltzer, JM, Ko, JH, Replogle, JM, et al. Single-chromosome gains commonly function as tumour suppressors. Cancer Cell 2017; 31: 240–255.
Google Scholar | Crossref | Medline32. Song, Y, Liu, C, Qi, H, et al. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn 2013; 33: 700–706.
Google Scholar | Crossref | Medline | ISI33. Hothorn, T, Hornik, K, Wiel, MAVD, et al. A Lego system for conditional inference. Am Stat 2006; 60: 257–263.
Google Scholar | Crossref | ISI34. Hothorn, T, Hornik, K, Zeileis, A. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat 2006; 15: 651–674.
Google Scholar | Crossref | ISI35. Liu, Y, Sun, J, Zhao, M. ONGene: A literature-based database for human oncogenes. J Genet Genomics 2017; 44: 119–121.
Google Scholar | Crossref | Medline36. Robin, X, Turck, N, Hainard, A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77.
Google Scholar | Crossref | Medline | ISI37. Høgdall, E. Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008; 20: 4–8.
Google Scholar | Crossref | Medline38. Partridge, EE, Greenlee, RT, Riley, TL, et al. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound in the prostate, lung, colorectal, and ovarian screening trial. Obstet Gynecol 2013; 121: 25–31.
Google Scholar | Crossref | Medline | ISI39. Goff, BA, Agnew, K, Neradilek, MB, et al.Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecol Oncol 2017; 147: 291–295.
Google Scholar | Crossref | Medline40. Potenza, E, Parpinel, G, Laudani, ME, et al. Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer. Int J Biol Markers 2020; 35: 20–27.
Google Scholar | SAGE Journals | ISI41. Christine, JY, Regan, S, Liu, G, et al. Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems. Mol Cytogenet 2018; 11: 31.
Google Scholar | Crossref | Medline42. Danner, BC, Hellms, T, Jung, K, et al. Prognostic value of chromosomal imbalances in squamous cell carcinoma and adenocarcinoma of the lung. Ann Thorac Surg 2011; 92: 1038–1043.
Google Scholar | Crossref | Medline43. Grade, M, Difilippantonio, MJ, Camps, J. Patterns of chromosomal aberrations in solid tumours. Recent Results Cancer Res 2015; 200: 115–142.
Google Scholar | Crossref | Medline44. Lo, FY, Chang, JW, Chang, IS, et al. The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. BMC Cancer 2012; 12: 235.
Google Scholar | Crossref | Medline45. Ried, T, Hu, Y, Difilippantonio, MJ, et al.The consequences of chromosomal aneuploidy on the transcriptome of cancer cells. Biochim Biophys Acta 2012; 1819: 784–793.
Google Scholar | Crossref | Medline46. Cai, Y, Zhai, J-J, Feng, B-B, et al. Expression of glucose transporter protein 1 and p63 in serous ovarian tumour. J Obstet Gynaecol Res 2014; 40: 1925–1930.
Google Scholar | Crossref | Medline47. Wen, Y, Hou, Y, Huang, Z, et al. SOX 2 is required to maintain cancer stem cells in ovarian cancer. Cancer Sci 2017; 108: 719–731.
Google Scholar | Crossref | Medline48. Belotte, J, Fletcher, NM, Alexis, M, et al. Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer. Reprod Sci 2015; 22: 38–46.
Google Scholar | SAGE Journals | ISI49. Au-Yeung, G, Lang, F, Azar, WJ, et al. Selective targeting of cyclin E1-amplified high- grade